09:15:55 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



News for U:GILD from 2023-03-30 to 2024-03-29 - 134 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-28 08:30U:GILDNews ReleaseFDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
2024-03-28 07:00U:GILDNews ReleaseGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
2024-03-28 07:00U:GILDNews ReleaseGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
2024-03-26 09:18U:GILDNews ReleaseWinn Awards Help Physicians Solve Healthcare Disparities
2024-03-22 09:18U:GILDNews ReleaseGilead Sciences Announces Completion of Acquisition of CymaBay
2024-03-19 09:08U:GILDNews ReleaseGilead Helps Launch Turkiye's First HIV Testing Week
2024-03-18 19:29U:GILDNews ReleaseCenter for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant
2024-03-12 08:47U:GILDNews ReleaseGilead Science Supports Increasing Diversity in Clinical Trials: 2024 Toward Health Equity Oncology Grant Supports 36 Global Organizations
2024-03-11 08:24U:GILDNews ReleaseGilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
2024-03-07 08:17U:GILDNews ReleaseGilead Sciences Aids in Reducing Cancer Care Disparities: Dale Shares Her Breast Cancer Journey and the Power of Information Sharing
2024-03-06 16:30U:GILDNews ReleaseBiktarvy(TM) Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
2024-03-06 10:25U:GILDNews ReleaseGilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
2024-03-06 08:00U:GILDNews ReleaseGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
2024-03-05 16:35U:GILDNews ReleaseNew Real-World Data Further Support the Use of Veklury(TM) (Remdesivir) for People Hospitalized With COVID-19
2024-03-05 16:30U:GILDNews ReleaseGilead's Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
2024-03-05 08:47U:GILDNews ReleaseGilead Sciences CEO on Company's Evolution and Commitment to the Bay Area
2024-02-29 08:33U:GILDNews ReleaseGilead Sciences: National Black HIV/AIDS Awareness Day
2024-02-28 17:17U:GILDNews ReleaseGilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
2024-02-27 10:00U:GILDNews ReleaseGilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
2024-02-26 16:05U:GILDNews ReleaseU.S. FDA Approves Expanded Indication for Gilead's Biktarvy(TM) to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
2024-02-26 08:30U:GILDNews ReleaseGilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
2024-02-26 08:16U:GILDNews ReleaseGilead Sciences and Black HIV/AIDS Awareness Day: Taking Action Toward Meaningful Change
2024-02-20 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conferences
2024-02-20 09:26U:GILDNews ReleaseGilead Named One of America ¢ € ™s Most JUST Companies by JUST Capital and CNBC
2024-02-13 08:33U:GILDNews ReleaseGilead Sets Sights on Hepatitis C Elimination As It Marks 10 Years of Curative Therapies
2024-02-12 08:30U:GILDNews ReleaseGilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
2024-02-09 11:00U:GILDNews ReleaseGilead Named One of America ¢ € ™s Most JUST Companies by JUST Capital and CNBC
2024-02-06 16:05U:GILDNews ReleaseGilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend
2024-02-06 16:02U:GILDNews ReleaseGilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
2024-02-06 08:18U:GILDNews ReleaseGilead Named One of Newsweek America ¢ € ™s Greatest Workplaces for Diversity
2024-02-01 16:31U:GILDNews ReleaseTed Love, MD, Joins Gilead Sciences ¢ € ™ Board of Directors
2024-01-30 08:30U:GILDNews ReleaseKite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta ‚ ® CAR T-cell Therapy
2024-01-30 08:11U:GILDNews ReleaseFrom the Margins: Gilead ¢ € ™s Book Uniquely Captures What It ¢ € ™s Like To Be Marginalized by Disease
2024-01-29 17:00U:GILDNews ReleaseGilead and Arcus Announce Amended Collaboration and Equity Investment
2024-01-29 17:00U:GILDNews ReleaseGilead and Arcus Announce Amended Collaboration and Equity Investment
2024-01-23 16:05U:GILDNews ReleaseGilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024
2024-01-23 09:52U:GILDNews ReleaseGilead Sciences: Art Captures the Experiences of Women Living With Metastatic Breast Cancer
2024-01-22 08:30U:GILDNews ReleaseGilead Provides Update on Phase 3 EVOKE-01 Study
2024-01-17 08:46U:GILDNews ReleaseGilead Sciences with Emma's Story: Self-Advocacy in Breast Cancer
2024-01-16 10:03U:GILDNews ReleaseGilead Sciences with Emma's Story: Self-Advocacy in Breast Cancer
2024-01-10 11:13U:GILDNews ReleaseGilead Pays Tribute to Patient Advocacy Work: Cara ¢ € ™s Story
2024-01-03 11:18U:GILDNews ReleaseGilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
2023-12-21 16:05U:GILDNews ReleaseU.S. FDA Approves Label Update for Kite ¢ € ™s Yescarta ‚ ® CAR T-Cell Therapy to Include Overall Survival Data
2023-12-21 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conference
2023-12-20 08:45U:GILDNews ReleaseRedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
2023-12-19 08:16U:GILDNews ReleaseGilead Supports World Health Organization To Bolster Public Health in Bangladesh
2023-12-19 07:00U:GILDNews ReleaseGilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
2023-12-12 13:40U:GILDNews ReleaseGilead's Legal Team Achieves Rigorous Diversity Certification
2023-12-12 08:11U:GILDNews ReleaseGilead's Legal Team Achieves Rigorous Diversity Certification
2023-12-11 21:00U:GILDNews ReleaseAnalyses of Kite ¢ € ™s Yescarta ‚ ® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
2023-12-11 19:30U:GILDNews ReleaseNew Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite ¢ € ™s Tecartus ‚ ® in Patients With Aggressive Blood Cancers
2023-12-11 17:45U:GILDNews ReleaseLong-Term Data for Kite ¢ € ™s Yescarta ‚ ® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
2023-12-11 12:00U:GILDNews ReleaseGilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
2023-12-06 21:09U:GILDNews ReleaseGilead's Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
2023-12-01 15:16U:GILDNews ReleaseGilead Employees Stitch Together To Create a Special Panel of the AIDS Quilt
2023-11-30 08:30U:GILDNews ReleaseGilead ¢ € ™s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
2023-11-28 08:17U:GILDNews ReleaseGilead's Ambition: To Help End the HIV Epidemic
2023-11-21 08:26U:GILDNews ReleaseGilead Sciences: Breaking Barriers to Breast Cancer Care in Rural Areas
2023-11-15 06:00U:GILDNews ReleaseKite and Arcellx Announce Expansion in Strategic Partnership
2023-11-15 06:00U:GILDNews ReleaseARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
2023-11-14 08:47U:GILDNews ReleaseGilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
2023-11-09 09:01U:GILDNews ReleaseGilead Sciences: Research Scholars Program Scientists Advancing HIV Research
2023-11-08 19:13U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conferences
2023-11-07 16:02U:GILDNews ReleaseGilead Sciences Announces Third Quarter 2023 Financial Results
2023-11-07 09:32U:GILDNews ReleaseGilead Sciences: Advancing Global Health Equity in Tropical Regions
2023-11-06 17:00U:GILDNews ReleaseGilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
2023-11-06 17:00U:GILDNews ReleaseGilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers
2023-11-03 11:00U:GILDNews ReleaseGilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting ‚ ® 2023
2023-11-02 09:15U:GILDNews ReleaseGilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
2023-10-31 08:22U:GILDNews ReleaseGilead's Commitment to Advancing Health Equity for Black Women and Ending the HIV Epidemic
2023-10-31 07:30U:GILDNews ReleaseKite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
2023-10-24 12:00U:GILDNews ReleaseGilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
2023-10-20 05:10U:GILDNews ReleaseNew Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca ‚ ® for Adults With Multi-Drug Resistant HIV
2023-10-19 03:00U:GILDNews ReleaseReal-World Evidence Reinforces Biktarvy ‚ ® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
2023-10-18 03:00U:GILDNews ReleaseGilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
2023-10-17 09:32U:GILDNews ReleaseGilead Sciences: Leading With Passion and Purpose: Sandra ¢ € ™s Story
2023-10-17 07:00U:GILDNews ReleaseGilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
2023-10-16 07:30U:GILDNews ReleaseGilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
2023-10-16 01:01U:GILDNews ReleaseGilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
2023-10-12 16:05U:GILDNews ReleaseGilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
2023-10-12 09:00U:GILDNews ReleaseGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
2023-10-03 08:30U:GILDNews ReleaseGilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
2023-10-02 09:00U:GILDNews ReleaseGilead Board Director Kevin E. Lofton Named to List of Influential Leaders
2023-09-19 08:30U:GILDNews ReleaseCHMP Adopts Positive Opinion to Extend the Use of Veklury ‚ ® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
2023-09-18 04:00U:GILDNews ReleaseKite ¢ € ™s Car T-cell Therapy Yescarta ‚ ® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
2023-09-10 03:01U:GILDNews ReleaseGilead ¢ € ™s Phase 2 EVOKE-02 Study of Trodelvy ‚ ® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA ‚ ® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
2023-09-07 20:55U:GILDNews ReleaseGilead Prices $2 Billion of Senior Unsecured Notes
2023-09-07 11:52U:GILDNews ReleaseGilead Sciences: How One School Has Transformed Education for First-Generation Students
2023-08-30 08:47U:GILDNews ReleaseGilead Sciences: Fifth Anniversary of COMPASS: Helping Address the HIV Epidemic in the U.S. South
2023-08-24 08:30U:GILDNews ReleaseFDA Approves Veklury ‚ ® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
2023-08-23 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conferences
2023-08-23 08:46U:GILDNews ReleaseHow Gilead ¢ € ™s Pharmaceutical Development and Manufacturing Team Delivers Transformative Medicines
2023-08-21 08:30U:GILDNews ReleaseGilead Announces Partial Clinical Hold for Magrolimab Studies in AML
2023-08-18 12:00U:GILDNews ReleaseGilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative ‚ ® on HIV in the Southern United States
2023-08-16 08:02U:GILDNews ReleaseGilead ¢ € ™s Focus on Ending the HIV Epidemic for Children Everywhere
2023-08-15 08:30U:GILDNews ReleaseGilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
2023-08-09 08:07U:GILDNews ReleaseGilead Sciences: A Cut Above the Rest: Innovative Barbershop Program Educates Indigenous Men About HIV
2023-08-03 16:02U:GILDNews ReleaseGilead Sciences Announces Second Quarter 2023 Financial Results
2023-08-02 13:59U:GILDNews ReleaseGilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
2023-07-27 13:23U:GILDNews ReleaseEuropean Commission Approves Gilead ¢ € ™s Trodelvy ‚ ® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
2023-07-24 19:00U:GILDNews ReleaseTwice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
2023-07-24 08:00U:GILDNews ReleaseCognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million
2023-07-23 21:51U:GILDNews ReleaseNew Biktarvy ‚ ® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
2023-07-23 17:00U:GILDNews ReleaseGilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
2023-07-21 17:02U:GILDNews ReleaseGilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
2023-07-20 12:00U:GILDNews ReleaseGilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
2023-07-20 12:00U:GILDNews ReleaseCenter for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
2023-07-20 12:00U:GILDNews ReleaseCenter for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
2023-07-19 10:20U:GILDNews ReleaseGilead Sciences: Putting a Spotlight on the Mental Health Needs of LGBTQ+ Youth
2023-07-19 08:30U:GILDNews ReleaseGilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
2023-07-14 16:05U:GILDNews ReleaseGilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
2023-07-14 08:00U:GILDNews ReleaseFDA Approves Veklury ‚ ® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
2023-07-13 06:00U:GILDNews ReleaseGilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
2023-06-23 08:11U:GILDNews ReleaseGilead Receives CHMP Positive Opinion for Trodelvy ‚ ® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
2023-06-23 02:30U:GILDNews ReleaseHepcludex ‚ ® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
2023-06-22 08:30U:GILDNews ReleaseKite Announces Completion of Marketing Authorization Transfer for Yescarta ‚ ® CAR T-cell Therapy in Japan
2023-06-14 03:00U:GILDNews ReleaseGilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
2023-06-06 10:45U:GILDNews ReleaseKite ¢ € ™s Tecartus ‚ ® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma
2023-06-05 12:30U:GILDNews ReleaseTrodelvy ‚ ® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
2023-06-05 11:25U:GILDNews ReleaseKite ¢ € ™s Yescarta ‚ ® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
2023-06-03 13:30U:GILDNews ReleaseGilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
2023-06-01 08:34U:GILDNews ReleaseGilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
2023-05-26 01:00U:GILDNews ReleaseCHMP Adopts Positive Opinion to Extend the Use of Veklury ‚ ® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
2023-05-25 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conference
2023-05-17 08:30U:GILDNews ReleaseGilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
2023-05-16 16:01U:GILDNews ReleaseGilead Appoints Cindy Perettie Executive Vice President of Kite
2023-05-15 08:30U:GILDNews ReleaseGilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
2023-05-15 08:30U:GILDNews ReleaseGilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
2023-05-09 08:30U:GILDNews ReleaseGilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
2023-05-04 07:00U:GILDNews ReleaseCHMP Adopts Positive Opinion Recommending Hepcludex ‚ ® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
2023-05-01 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conferences
2023-04-27 16:02U:GILDNews ReleaseGilead Sciences Announces First Quarter 2023 Financial Results
2023-04-16 04:00U:GILDNews ReleaseVeklury ‚ ® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
2023-04-13 16:05U:GILDNews ReleaseGilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023